dihydroergotamine mesylate

dihydroergotamine mesylate

[dīhī′drō·ərgot′əmēn me′si lāt]
an ergot alkaloid causing vasoconstriction through stimulation of several types of receptors, including alpha-adrenergic receptors and serotonin receptors.
indications It is prescribed for the treatment of migraine and vascular headache.
contraindications Cardiovascular disease, hypertension, liver or kidney dysfunction, sepsis, pregnancy, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse reactions are gangrene and the toxicity of the ergot alkaloids.

Migranal

A nasal spray formulation of an ergot compound used to manage migraines, but not hemiplegic or basilar migraines and not as prophylaxis.
 
Adverse effects
Rarely: cardiac events, including coronary artery vasospasm, transient myocardial ischaemia or infarction, ventricular tachycardia and ventricular fibrillation. More commonly: burning sensation, dysgeusia, diarrhoea, dizziness, drowsiness, dry mouth, hot flushes, irritation, nasal congestion or dryness, nasal discharge, nausea, sinusitis, sore throat, exhaustion, weakness.

dihydroergotamine mesylate

(dī-hī″drō-ĕr-gŏt′ă-mēn)
A vasoconstrictor used in treating migraine.
Mentioned in ?
References in periodicals archive ?
Nasdaq: MAPP) today reported results from a pharmacodynamics (PD) trial comparing the acute effects on pulmonary artery pressure of LEVADEX(TM), dihydroergotamine mesylate (DHE) administered intravenously (IV) and placebo.
If headaches recur, treat attacks earlier, increase the dose, switch triptans, particularly to naratriptan or frovatriptan, add an NSAID, or switch to dihydroergotamine mesylate, Dr.
Nasdaq: MAPP) today announced results from a clinical trial comparing the pharmacokinetics (PK) and safety of LEVADEX(TM) orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers.
The Company's lead product candidates during the Class Period were MT-100, a proprietary formulation containing metoclopramide hydrochloride and naproxen sodium, and MT-300, a pre-filled syringe containing dihydroergotamine mesylate, or DHE.
MT 300 is being developed as a new formulation of dihydroergotamine mesylate (DHE) in a prefilled syringe for the acute treatment of migraine.
Pharmacokinetics (PK) trial: This single dose, open-label, crossover trial is designed to compare the PK of LEVADEX to intravenous dihydroergotamine mesylate (IV DHE) in both smokers and non-smokers.
MT 300 is being developed as an improved and highly purified formulation of dihydroergotamine mesylate (DHE) in a convenient pre-filled syringe that is suitable for at-home use.
Nasdaq: MAPP) today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX(TM) orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography.
MT 300, a proprietary formulation of injectable dihydroergotamine mesylate (DHE) in a pre-filled syringe, is being developed to provide long-lasting pain relief for patients needing a convenient injectable therapy for severe migraine attacks.
Nasdaq: MAPP) today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX(TM) orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers.
MT 300 is being developed as a new, improved product containing dihydroergotamine mesylate (DHE) in a convenient, easy to use pre-filled syringe.
The poster presentation, which was accepted as a late-breaker, is entitled Rapid and Sustained Clinical Efficacy and Safety of Inhaled Dihydroergotamine Mesylate via a Novel Inhaler (Tempo(TM) Inhaler), Poster ID S77, and will be presented on Saturday, June 9, 2007 from 12:00 to 1:00pm CDT.